Nomura began coverage on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) in a report published on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $43.00 target price on the biopharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on SCMP. BidaskClub raised Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday, December 12th. ValuEngine raised Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Thursday, December 7th. Mizuho lifted their price target on Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the stock a neutral rating in a research note on Friday, December 8th. Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, December 7th. Finally, B. Riley lifted their price target on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a buy rating in a research note on Wednesday, December 6th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $21.00.

Sucampo Pharmaceuticals (SCMP) opened at $16.70 on Monday. The firm has a market capitalization of $781.15, a PE ratio of 11.47, a P/E/G ratio of 4.99 and a beta of 1.47. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.70. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. Sucampo Pharmaceuticals’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted $0.30 EPS. analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the sale, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.13% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. acquired a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter valued at about $117,000. Pinnacle Associates Ltd. acquired a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter valued at about $122,000. Trexquant Investment LP acquired a new stake in shares of Sucampo Pharmaceuticals during the 3rd quarter valued at about $122,000. SG Americas Securities LLC lifted its holdings in shares of Sucampo Pharmaceuticals by 5.6% during the 2nd quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 631 shares during the last quarter. Finally, Nine Chapters Capital Management LLC acquired a new stake in shares of Sucampo Pharmaceuticals during the 3rd quarter valued at about $127,000. Hedge funds and other institutional investors own 65.29% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/sucampo-pharmaceuticals-scmp-earns-buy-rating-from-analysts-at-nomura/1775795.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.